Oncology Learning Network
@OncLearnNetwork
Oncology Learning Network® is an online resource for the latest updates in oncology practice. Official digital home for @GreatDebatesCME and @LLMCongress.
You might like
Today we recognize World Pancreatic Cancer Day and everyone affected by this difficult disease. Awareness can save lives by helping more people recognize symptoms early and seek care sooner. #WorldPancreaticCancerDay #Oncology #CancerAwareness
The implementation of #EMR-integrated clinical decision pathways improved workflow #efficiency, dynamic responsiveness, and multidisciplinary collaboration across a large multisite oncology center. Learn more: hubs.ly/Q03TlDYz0
Catherine Diefenbach, MD, shares the latest insights into the treatment and management of recurrent diffuse large B-cell lymphoma at the 2025 Lymphoma, Leukemia & Myeloma Congress. Learn more: hubs.ly/Q03T5rp00
The @US_FDA has approved the first interchangeable biosimilar to #pertuzumab for patients with HER2-positive breast cancer. Learn more: hmpgloballearningnetwork.com/site/onc/fda-a… #medtwitter #onctwitter #FDAapprovals #biosimilars
The FDA approved #ziftomenib, a menin inhibitor, for patients with relapsed/refractory #AML who have an NPM1 mutation and have no satisfactory alternative treatment options. Learn more: hubs.ly/Q03T28sD0
This month, we recognize #StomachCancerAwarenessMonth and everyone affected by this difficult diagnosis. #StomachCancer is too often found late, too rarely talked about. Let’s change that. #Oncology #CancerAwareness
Tyrosine kinase inhibitors (TKIs) can change outcomes but managing them takes precision and vigilance. At the #OLNAPPInstitute, Co-Chair Beth Sandy, MSN, CRNP, FAPO explores how APPs can balance efficacy, toxicity & patient engagement in TKI therapy. hubs.ly/Q03SW_SN0
Rani Khetarpal, MBA, shares an insider look at #highlights to be presented at the 2025 #AONN+ Annual Conference in New Orleans, Louisiana. Learn more: hubs.ly/Q03SSYnr0
Results from a phase 3 trial demonstrated that #dabrafenib plus #trametinib significantly improved survival and response rates among patients with BRAF V600E-mutated, radioiodine-refractory thyroid cancer. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter
According to results from the ENAVEN-AML trial, #enasidenib combined with venetoclax demonstrated clinical activity and manageable safety for R/R IDH2-mutated acute myeloid leukemia. Learn more: hubs.ly/Q03SGmkG0
The Debates Return in 2026! Get ready for another year of thought-provoking, debate-driven education. 🗓 Mar 14–15 | Miami, FL 🗓 Sept 26–27 | New York, NY Now featuring five focus areas: GI, breast, gynecologic, lung, and GU cancers hubs.ly/Q03SxB710 #OLNGreatDebates
Among patients with #myelofibrosis refractory or intolerant to ruxolitinib, the JAK/ROCK inhibitor #rovadicitinib demonstrated promising clinical activity and safety in early clinical trials. Learn more: hubs.ly/Q03SsLG90
Results from the #AMALEE trial demonstrate that 400 mg of #ribociclib plus #NSAI achieved similar efficacy with fewer side effects than the 600 mg standard in HR-positive, HER2-negative advanced breast cancer. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #onctwitter #medtwitter
Today we shine a light on neuroendocrine tumor (NET) awareness. Early recognition and understanding can change lives. Let’s keep the conversation going. #NETCancerDay #Oncology #CancerAwareness
This week, we celebrate National #NursePractitionerWeek and recognize the NPs who bring compassion, expertise, and consistency to every corner of oncology care. Thank you for being the trusted voices behind proven care. #OncologyNPs #Oncology #CancerCare #HealthcareHeroes
The way we treat high-risk CSCC is changing, and it starts with collaboration. On December 4, experts in dermatology, oncology, and surgery will come together to share strategies that redefine how complex CSCC is managed. Register Now → hubs.ly/Q03S5ljk0
Rani Khetarpal, MBA, shares an insider look at #highlights to be presented at the 2025 #AONN+ Annual Conference in New Orleans, Louisiana. Learn more: hubs.ly/Q03ScXQf0
Administration of consolidative thoracic radiotherapy following first-line #chemoimmunotherapy demonstrated promising efficacy and safety among patients with extensive-stage #SCLC. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter
Emotional distress doesn’t stop w/ the patient. It reaches caregivers, families & the clinicians who walk beside them. At #OLNAPPInstitute, Holly Stewart shares ways #APPs can recognize distress, respond w/ compassion & care for their own well-being too. hubs.ly/Q03RFS1z0
On November 6, 2025, the FDA granted approval to #daratumumab and hyaluronidase-fihj for the treatment of patients with high-risk smoldering multiple myeloma. Learn more: hubs.ly/Q03S4NhM0
United States Trends
- 1. $BNKK N/A
- 2. #MondayMotivation 34.9K posts
- 3. Good Monday 46.2K posts
- 4. Victory Monday 2,271 posts
- 5. #NXXTCall N/A
- 6. #ChaoVendeHumo 1,913 posts
- 7. #MondayVibes 2,354 posts
- 8. #DestinyClinicxWilliamEst 496K posts
- 9. Anthony Joshua 3,684 posts
- 10. $NXXT N/A
- 11. Guma 18.8K posts
- 12. Peyz 7,387 posts
- 13. House Republicans 35.5K posts
- 14. Project Prometheus N/A
- 15. Sanders 59.6K posts
- 16. Goff 20.8K posts
- 17. Sheikh Hasina 28.2K posts
- 18. New Week 208K posts
- 19. Baker 18.3K posts
- 20. Bangladesh 82.8K posts
You might like
-
Mike Pishvaian
@MPishvaian -
Journal of Clinical Oncology
@JCO_ASCO -
Dr. jordan berlin
@jordanberlin5 -
ESMO Open
@ESMO_Open -
Sam Klempner
@KlempnerSam -
OncLive.com
@OncLive -
Kohei shitara
@KoheiShitara -
Great Debates
@GreatDebatesCME -
Eileen M O’Reilly
@EileenMOReilly -
Oncology Brothers
@OncBrothers -
Ghassan Abou-Alfa
@GABOUALFA -
OncologyEducation
@OncEd -
Benjamin Weinberg, MD, FACP
@benweinbergmd -
Lizzy Smyth
@LizzySmyth1 -
Cancer Immunology Research
@CIR_AACR
Something went wrong.
Something went wrong.